| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 16 Nov 2026 |
Form 4: Williams Gregg, Director
Bought 48,100 shares ($47.8K) |
| 13 Nov 2026 |
Form 4: Dwyer Donald, Chief Business Officer
Bought 20,000 shares ($19.6K) |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Top-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated for announcement later this week |
| 12 Nov 2026 | 10-Q |
| 30 Oct 2026 |
8-K: Regulation FD Disclosure
As previously disclosed, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), and CLRO Merger Sub, Inc. (“Mer... |
| 29 Oct 2026 |
8-K: Regulation FD Disclosure
Vivani Medical, Inc. (“Vivani”) from time to time presents, and/or distributes to the investment community at various industry and other conferences, slide presentations to provide updates and summaries of its business. A copy of these s... |
| 19 Oct 2026 |
Form 4: Mendelsohn Aaron, Director
Gave 20,000 shares as a gift |
| 25 Sep 2026 | 424B5 |
| 16 Sep 2026 |
8-K: Regulation FD Disclosure
As previously disclosed, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), and CLRO Merger Sub, Inc. (“Mer... |
| 17 Aug 2026 |
8-K: Regulation FD Disclosure
Vivani Medical, Inc. (“Vivani”) from time to time presents, and/or distributes to the investment community at various industry and other conferences, slide presentations to provide updates and summaries of its business. A copy of these s... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 |
| 13 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Regulation FD Disclosure
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management |
| 30 Jul 2026 |
Form 4: Dwyer Donald, Chief Business Officer
Granted 70,000 Common Stock Option · Granted 35,000 RSUs |
| 30 Jul 2026 |
Form 4: Porter Lisa Ellen, Chief Medical Officer
Granted 80,000 Common Stock Option · Granted 40,000 RSUs |
| 30 Jul 2026 |
Form 4: Baldor Anthony, Chief Financial Officer
Granted 75,000 Common Stock Option · Granted 37,500 RSUs |
| 30 Jul 2026 |
Form 4: Le Truc, Chief Operations Officer
Granted 160,000 Common Stock Option · Granted 80,000 RSUs |
| 30 Jul 2026 |
Form 4: Mendelsohn Adam, Director
Granted 200,000 Common Stock Option · Granted 100,000 RSUs |
| 28 Jul 2026 |
Form 4: Bradbury Daniel, Director
Granted 7,965 Non-Qualified Stock Option (right to buy) ($10.4K) |
Loading...